Article Text

Download PDFPDF
Patient experiences in high-grade gliomas: from symptoms to radiotherapy
  1. Jonathan Chainey1,
  2. Michael J Kim2,
  3. Vivien Ka-Ying Chan2 and
  4. Karolyn Au2
  1. 1University of Toronto, Toronto, Canada
  2. 2University of Alberta, Edmonton, Canada
  1. Correspondence to Dr Jonathan Chainey; jonathanchainey.md{at}gmail.com

Abstract

Objectives Little is known in the literature about felt experience and supportive care needs of patients with new diagnosis of adult-type diffuse gliomas Central Nervous System WHO grades 3 and 4. The purpose of this study is to influence clinicians’ attitudes and facilitate the referral process and the development of support services by better understanding the patient’s journey.

Methods Adult patients with a new histopathological diagnosis of high-grade glioma, who underwent radiotherapy, participated in a semistructured, face-to-face interview. Different segments of the patient’s journey were explored focusing on patient’s emotions, interactions with healthcare providers, satisfaction during the process and access to supports. Descriptive thematic analysis in the tradition of grounded theory was performed.

Results Fifteen patients were interviewed, and four themes were emerged from the analysis. First, information conveyed by the medical team was frequently disconnected from patients’ understanding regarding diagnosis and treatment. Second, specific events created a lasting impression that the medical system, and at times medical care providers, lacked empathy. Third, patients’ perceptions of shortcomings within the medical system led to decreased trust, particularly regarding the follow-up process. Finally, although respondents identified multiple inadequacies during their journey, they nonetheless acknowledged the great support and quality of services they received.

Conclusions This study provides insight into patients’ experiences and perceived shortcomings of the medical system, from the time of presentation until the end of radiotherapy treatment in patients with new diagnosis of high-grade glioma. These findings should influence clinicians’ attitudes and guide systematic changes including delivery of information and the referral process.

  • Brain
  • Neurological conditions
  • Psychological care
  • Quality of life

Data availability statement

Interview guide will be provided as supplementary material. Anonymised interview transcripts of the 15 study participants can be provided if requested. No data are available.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Data availability statement

Interview guide will be provided as supplementary material. Anonymised interview transcripts of the 15 study participants can be provided if requested. No data are available.

View Full Text

Footnotes

  • X @jo_chainey

  • Collaborators There were no collaborators for this project.

  • Contributors Experimental design: JC, KA, MJK. Interview process: JC, VK-YC. Analysis and interpretation of the data: JC, KA, VK-YC, MJK. Manuscript: JC, KA, VK-YC, MJK. There were non-author contributors or group author contributors. JC is the guarantor.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer-reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.